Loading...

LYEL LYELL IMMUNOPHARMA INC Product Launches 8-K Filing

LYLL

LYL

LYELL IMMUNOPHARMA INC

(LYEL)

2024 8-K

Show Summary

Show Summary

Merger of Equals

New Clinical Data

Financial Statements

Facility Closure

Financial Results

Acquisition Completed

Clinical Data Release

Board Resignation

Financial Results

Merger Completion

Merger Agreement

Earnings Report

Phase 1 Trial Data Announce...

Earnings Report

Earnings Reports

Repricing of Underwater Opt...

Financial Results Announcement

Investor Presentation

Earnings Report

Annual Meeting of Stockholders

Resignation of Chief Legal ...

Earnings Report

Earnings Reports

External Links:

Lyell Immunopharma presented positive initial clinical data for its IMPT-314 treatment targeting large B-cell lymphoma at the 2024 ASH Annual Meeting, showcasing its potential to improve response rates compared to existing therapies.

AI Assistant

LYELL IMMUNOPHARMA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.